Filtered By:
Drug: Diovan

This page shows you your search results in order of date. This is page number 4.

Order by Relevance | Date

Total 78 results found since Jan 2013.

Does Neprilysin Inhibition Potentiate or Minimize the Adverse Effects of Glucagon-Like Peptide-1 Receptor Agonists in Chronic Heart Failure?
Heart failure and diabetes commonly coexist, and therefore, drugs that favorably influence the natural history of each of these two disorders are likely to be prescribed together.1 In patients with type 2 diabetes, glucagon-like peptide-1 (GLP-1) receptor agonists decrease the risk of major adverse cardiovascular events,2,3 and liraglutide is approved to reduce cardiovascular death, nonfatal myocardial infarction and nonfatal stroke.4 Analogously, in patients with chronic heart failure and a reduced ejection fraction, neprilysin inhibition has been shown to decrease the risk of cardiovascular death and hospitalization for ...
Source: Journal of Cardiac Failure - January 3, 2018 Category: Cardiology Authors: Milton Packer Tags: Editorial Source Type: research

Vascular protective effects of aqueous extracts of Tribulus terrestris on hypertensive endothelial injury
In conclusion, TT demonstrated anti-hypertensive and endothelial protective effects by regulating Erk2, FAK and NF-κB p65.
Source: Chinese Journal of Natural Medicines - September 21, 2017 Category: Complementary Medicine Source Type: research

Abstract P421: The Effects of Dual Angiotensin Receptor and Neprilysin Inhibitor on Organoprotection in Experimental Model of Chronic Heart Failure Session Title: Renin-Angiotensin System
The cardiac effects of dual angiotensin receptor and neprilysin inhibitor (LCZ696) as a novel therapeutic approach for inhibition of renin-angiotensin system was assessed in volume overload-induced chronic heart failure (CHF) in hypertensive Ren2 transgenic rats (TGR) with aorto-caval fistula (ACF) and compared with valsartan (VAL). CHF model was induced by ACF in male TGR at 8 weeks of age. After 5 weeks of ACF induction, LCZ696 was administered in standard dosing at 68 mg/kg/day and VAL at 31 mg/kg/day for next 15 weeks to assess the effect on mortality. In second series, 12 weeks after ACF, the animals were anaesthetize...
Source: Hypertension - September 14, 2017 Category: Cardiology Authors: Libor Kopkan, Lenka Hoskova, Voȷtech Melenovsky, Zuzana Huskova, Ludek Cervenka Tags: Poster Abstract Presentations Source Type: research

Effectiveness and safety of valsartan/amlodipine in hypertensive patients with stroke: China Status II subanalysis
Abstract: High blood pressure (BP) is a major risk factor associated with stroke in China. This is a subanalysis of patients from the China Status II study, aimed to evaluate the effectiveness and safety of valsartan/amlodipine (Val/Aml) single-pill combination (SPC) in hypertensive patients with different stroke subtypes (hemorrhagic, ischemic, or mixed). China Status II was a multicenter, postmarketing, prospective observational study in hypertensive patients uncontrolled on monotherapy. The study was an 8-week open-label treatment period with 2 4-week follow-ups. Change in BP from baseline to weeks 4 and 8, BP control ...
Source: Medicine - June 1, 2017 Category: Internal Medicine Tags: Research Article: Observational Study Source Type: research

The effects of sacubitril/valsartan on coronary outcomes in PARADIGM-HF
Conclusions Compared with enalapril, sacubitril/valsartan reduced the risk of both the primary endpoint and a coronary composite outcome in PARADIGM-HF. Additional studies on the effect of sacubitril/valsartan on atherothrombotic outcomes in high risk patients are merited.
Source: American Heart Journal - March 14, 2017 Category: Cardiology Source Type: research

Hemopericardium under dabigatran for stroke prevention in atrial fibrillation
We report a polymorbid 75-year old male under a therapy with dabigatran, valsartan, amlodipine, nicorandil, furosemide, atorvastatin, bisoprolol, metformin, tizanidine, pantoprazole, and tramadol. He suffered from chest pain for 4 months. Coronary angiography showed only ectatic coronary arteries. He started taking nonsteroidal anti-inflammatory drugs. He was hospitalized because of dyspnea starting 10 days before admission, melena, and renal failure. Hemopericardium was diagnosed and pericardiocentesis yielded 2000 ml hemorrhagic fluid. Review of previous echocardiograms showed a 4 mm echo-free space, epicardial fat o...
Source: Blood Coagulation and Fibrinolysis - February 11, 2017 Category: Hematology Tags: Case Reports Source Type: research

International Variation in Outcomes Among People with Cardiovascular Disease or Cardiovascular Risk Factors and Impaired Glucose Tolerance: Insights from the NAVIGATOR Trial Epidemiology
BackgroundRegional differences in risk of diabetes mellitus and cardiovascular outcomes in people with impaired glucose tolerance are poorly characterized. Our objective was to evaluate regional variation in risk of new‐onset diabetes mellitus, cardiovascular outcomes, and treatment effects in participants from the NAVIGATOR (Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research) trial.Methods and ResultsNAVIGATOR randomized people with impaired glucose tolerance and cardiovascular risk factors or with established cardiovascular disease to valsartan (or placebo) and to nateglinide (or placebo) with a ...
Source: JAHA:Journal of the American Heart Association - January 13, 2017 Category: Cardiology Authors: Harumi Higuchi dos Santos, M., Sharma, A., Sun, J.-L., Pieper, K., McMurray, J. J. V., Holman, R. R., Lopes, R. D. Tags: Cardiovascular Disease, Diabetes, Type 2, Risk Factors Original Research Source Type: research

Focus on the Novel Cardiovascular Drug LZC696: from Evidence to Clinical Consideration
AbstractLCZ696, a first-in-class angiotensin receptor neprilysin inhibitor (ARNI), is comprised of the angiotensin receptor blocker valsartan and the neprilysin inhibitor pro-drug sacubitril (AHU377). After oral administration, AHU377 is rapidly metabolized to the active neprilysin inhibitor LBQ657. LCZ696 exerts its effects of diuresis, natriuresis, vasodilation and aldosterone secretion inhibition through simultaneous renin-angiotensin-aldosterone system (RAAS) blockade and natriuretic peptides system (NPS) enhancement. Powerful evidence including PARAMETER and PRARDIGM-HF trials have shown that LCZ696 outperforms RAAS i...
Source: Cardiovascular Drugs and Therapy - November 17, 2016 Category: Cardiology Source Type: research

Sacubitril/Valsartan Reduces Serum Uric Acid Level, an Independent Predictor of Adverse Outcomes in HFrEF: Results From PARADIGM-HF
We examined the association between UA level and outcomes in patients with HFrEF and the effect of sacubitril/valsartan on UA concentrations in patients in PARADIGM-HF. Methods: The association between UA and the primary composite outcome of cardiovascular (CV) death or HF hospitalization, its components and all-cause mortality was examined among 8213 patients using quintiles of UA (Q1:  
Source: Journal of Cardiac Failure - July 23, 2016 Category: Cardiology Authors: Ulrik M. Mogensen, Pardeep S. Jhund, Lars K øber, Margaret F. Prescott, Martin P. Lefkowitz, Jean-Lucien Rouleau, Scott D. Solomon, Karl Swedberg, Michael R. Zile, Milton Packer, John J.V. McMurray Source Type: research

Cost-effectiveness of amlodipine compared with valsartan in preventing stroke and myocardial infarction among hypertensive patients in Taiwan
Source: International Journal of General Medicine - May 31, 2016 Category: Journals (General) Tags: International Journal of General Medicine Source Type: research

Cardiovascular outcomes at different on-treatment blood pressures in the hypertensive patients of the VALUE trial
Conclusions In the high CV risk, hypertensives of the VALUE trial reducing BP consistently to <140/90 mmHg had marked beneficial effects both when data were calculated as proportion of visits at BP target or as on-treatment mean BP. Reducing BP to <130/80 mmHg led only to some possible further benefit on stroke, whereas the risk of other outcomes remained substantially similar to or slightly greater than that seen at the higher target. Thus, aggressive BP reductions when CV risk is high may not offer substantial advantages, except perhaps in patients or conditions in which stroke risk is particularly common.
Source: European Heart Journal - March 21, 2016 Category: Cardiology Authors: Mancia, G., Kjeldsen, S. E., Zappe, D. H., Holzhauer, B., Hua, T. A., Zanchetti, A., Julius, S., Weber, M. A. Tags: Hypertension Source Type: research

Predictors of cardiac morbidity in diabetic, new-onset diabetic and non-diabetic high-risk hypertensive patients: The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial.
Authors: Aksnes TA, Kjeldsen SE, Rostrup M, Holzhauer B, Hua TA, Julius S Abstract Diabetic and new-onset diabetic patients with hypertension have higher cardiac morbidity than patients without diabetes. We aimed to investigate whether baseline predictors of cardiac morbidity, the major constituent of the primary endpoint in the Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial, were different in patients with diabetes and new-onset diabetes compared to patients without diabetes. In total, 15,245 high-risk hypertensive patients in the VALUE trial were followed for an average of 4.2 years. At baselin...
Source: Blood Pressure - February 14, 2016 Category: Hematology Tags: Blood Press Source Type: research

No evidence for a J-shaped curve in treated hypertensive patients with increased cardiovascular risk: The VALUE trial.
In conclusion, patients in BP strata ≥ 150/90 mmHg, but not patients in BP strata < 130/70 mmHg, were at increased risk for adverse outcomes in this hypertensive, high-risk population. Although benefit in preventing MI in relation to preventing stroke levels off for the lowest BPs, these data provide no support for a J-curve in the treatment of high-risk hypertensive patients . The increase in the ratio of MI to stroke with lower DBP indicates target organ heterogeneity in that the optimal on-treatment DBP for cerebroprotection is below that for cardioprotection. PMID: 26511535 [PubMed - in process]
Source: Blood Pressure - February 14, 2016 Category: Hematology Tags: Blood Press Source Type: research

Polypill for the prevention of cardiovascular disease (PolyIran): study design and rationale for a pragmatic cluster randomized controlled trial
Conclusion The infrastructure of GCS and the primary health care system in Iran enabled the conduct of this pragmatic large-scale trial. If the polypill strategy proves effective, it may be implemented to prevent cardiovascular disease in developing countries.
Source: European Journal of Preventive Cardiology - November 9, 2015 Category: Cardiology Authors: Ostovaneh, M. R., Poustchi, H., Hemming, K., Marjani, H., Pourshams, A., Nateghi, A., Majed, M., Navabakhsh, B., Khoshnia, M., Jaafari, E., Mohammadifard, N., Malekzadeh, F., Merat, S., Sadeghi, M., Naemi, M., Etemadi, A., Thomas, G. N., Sarrafzadegan, N. Tags: Original scientific paper Source Type: research

Upstream therapeutic strategies of Valsartan and Fluvastatin on Hypertensive patients with non-permanent Atrial Fibrillation (VF-HT-AF): study protocol for a randomized controlled trial
This study was designed to examine whether valsartan or fluvastatin can reduce the risk of non-permanent AF in patients with hypertension.Methods/designThe VF-HT-AF study is a multicenter, randomized, open-label, four-arm parallel group study with comparative evaluation of valsartan and fluvastatin as upstream therapies for the treatment of non-permanent AF complicated by hypertension. The primary outcome measure is change in the development of paroxysmal AF into persistent or permanent AF, the development of persistent AF to permanent AF, and change in incidence of overall and persistent AF recurrence, as evaluated by 7-d...
Source: Trials - August 7, 2015 Category: Journals (General) Authors: Wen-Wei QiTong LiuGang XuLi-Feng LiYing-Zi LiangLan YeGuang-Ping Li Source Type: research